CVS Health Corp (NYSE:CVS) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a report issued on Wednesday. The firm presently has a $85.96 target price on the pharmacy operator’s stock. Vetr‘s price objective suggests a potential upside of 12.62% from the stock’s previous close. Several other equities […]